Interesting thought, particularly as we saw recently new holders at +5% stake and since then still someone buying up large. A $250m company isn't a huge purchase for some big health players out there, and yet it is cash flow positive and provides footing into a relatively niche market with growing potential. Won't be getting my vote for less than 80c per share!
Interesting thought, particularly as we saw recently new holders...
Add to My Watchlist
What is My Watchlist?